Listen to this Blog
📊 Pharmaceuticals Industry Report – H1 & Q2 FY26
🌐 Industry Overview
Market Cap (Sector): ₹22,74,124 Cr
Sales: H1 ₹2,20,982 Cr (+10.9% YoY), Q2 ₹1,13,212 Cr (+13.3% YoY)
Profit: H1 ₹32,887 Cr (+4.2% YoY), Q2 ₹17,605 Cr (+10.6% YoY)
Margins: H1 14.9% (↓96 bps), Q2 15.6% (↓38 bps)
🏆 Market Cap Leaders
➡️ Top 10 companies = ~49% of industry market cap.
📈 Growth Leaders (H1 FY26)
🔬 Laurus Labs: Sales +33%, Profit +980% 🚀
🌐 Lupin: Sales +18%, Profit +63% 💪
🔬 Divi’s Labs: Sales +15%, Profit +31% 🌟
🧬 Zydus Life: Sales +11%, Profit +17% 👍
💊 Torrent Pharma: Sales +13%, Profit +25% 📊
⚠️ Weakness: Sun Pharma (profit -8%), Mankind (profit -20%), Dr Reddy’s (flat profit).
⚡ Quarterly Momentum (Q2 FY26)
🔬 Laurus Labs: Profit +978% 🚀
🌐 Lupin: Profit +73% 💪
🧬 Zydus Life: Profit +38% 👍
🧪 Divi’s Labs: Profit +35% 🌟
🧪 Biocon: Profit +289% 🔄 rebound
💊 Glenmark: Sales +76%, Profit +72% ⚡
⚠️ Draggers: Mankind (profit -21%), Dr Reddy’s (profit -0.4%).
🧭 Weighted Impact (Investor Lens)
🌞 Sun Pharma: Largest weight, but weak profit leverage.
🔬 Divi’s Labs: Strong efficiency, margin expansion.
🌐 Lupin: Consistent compounding, strong leverage.
🔬 Laurus Labs: Dominates industry profit growth despite smaller size.
🧬 Zydus Life: Balanced growth + margin expansion.
🧪 Biocon: Turnaround in Q2, watch sustainability.
💡 Investor Recommendation
Core Quality Anchor: 🔬 Divi’s Labs (already held) – stable API/CDMO leader.
Growth Leverage: 🌐 Lupin – consistent compounding across H1 & Q2.
Turnaround Alpha: 🔬 Laurus Labs – extraordinary profit momentum.
Defensive Balance: 🏥 Abbott India / 💊 Alkem – steady margins, mid-teens growth.
Caution: 🌞 Sun Pharma (margin pressure), 👨⚕️ Mankind (profit decline), 🧪 Dr Reddy’s (flat earnings).
📌 Summary for Investors
Best Buy (with Divi’s Labs): 🌐 Lupin + 🔬 Laurus Labs
Balanced Portfolio: Divi’s (quality anchor) + Lupin (growth) + Laurus (turnaround)
Optional Defensive Add: Abbott India / Alkem for stability
Avoid Overweight: Sun Pharma, Mankind, Dr Reddy’s
Report Created By: Kinjal Bhatt
Disclosure:
This update is provided solely for informational purposes.
It does not constitute investment advice.
Readers should conduct their own research before making any investment decisions.
.jpg)
